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proaches. We sought to examine the use of clinical trials as a tool for CER, particularly in mental health.
Study Design and Setting: Examination of three ongoing randomized clinical trials in psychiatry addressing issues that would pose
difficulties for nonexperimental CER methods.
Results: Existing statistical approaches to nonexperimental data appear insufficient to compensate for biases that may arise when the
pattern of missing data cannot be properly modeled such as when there are no standards for treatment, when affected populations have
limited access to treatment, or when there are high rates of treatment dropout.
Conclusion: Clinical trials should retain an important role in CER, particularly in cases of high disorder prevalence, large expected
effect sizes, difficult-to-reach populations, or when examining sequential treatments or stepped-care algorithms. Progress in CER on mental
health will require careful consideration of appropriate selection between clinical trials and nonexperimental designs and on allocation of
research resources to optimally inform key treatment decisions for each patient.  2013 Elsevier Inc. All rights reserved.
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Increased interests in improving quality of care, control-
ling health care costs, and providing personalized treatment
have produced a growing emphasis on comparative effec-
tiveness research (CER) [1]. In the field of medicine, clin-
ical trials have traditionally been considered the gold
standard in establishing the efficacy, effectiveness, and
cost-effectiveness of treatment and preventive interven-
tions. However, clinical trials are often expensive and
fraught with potential difficulties, including selecting an
appropriate control group, achieving adequate recruitment
and retention of participants, monitoring fidelity in the de-
livery of the interventions, ensuring statistical power for hy-
potheses testing, and addressing concerns about multiple
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http://dx.doi.org/10.1016/j.jclinepi.2013.02.013Furthermore, clinical trials generally take several years to
complete, and results may not be available for several addi-
tional years after study completion.
Partly, for these reasons, observational studies have be-
come increasingly popular in CER. For example, in a recent
JAMA issue focused on CER, all the original contributions
described observational studies [4e8]. Observational studies
offer important advantages over clinical trials. They can of-
ten accrue large sample sizes at a fraction of the cost of clin-
ical trials, attain broader geographic diversity and
generalizability of results, and provide answers to research
questions with minimal delay. They can serve as an alter-
native to randomization when this may not be feasible,
ethical, or acceptable to patients. Several statistical tech-
niques have been developed to compensate for the lack of
randomization, including stratification, instrumental variable
(IV) techniques, and high-dimensional propensity scores
[9,10]. These techniques seek to minimize the threats of con-
founding by treatment indication and illness severity that of-
ten arise in observational, but not in random assignment,
designs. However, despite methodological advances these
techniques may fail to overcome the biases inherent in obser-
vational research [11]. IV techniques assume that the instru-
ment exerts its effect exclusively through the treatment
assignment, an assumption that is often impossible to verify.
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 Existing statistical approaches to nonexperimental
data appear insufficient to compensate for potential
biases that may arise when the pattern of missing
data cannot be properly modeled.
 Clinical trials should retain an important role in
CER, particularly in cases of high disorder preva-
lence, large expected effect sizes, difficult to reach
populations, or when examining sequential treat-
ments or stepped-care algorithms.
 There is a need for careful consideration of appro-
priate selection between clinical trials and nonex-
perimental designs and on allocation of research
resources to optimally inform key treatment deci-
sions for each individual patient.
 Funding agencies should also consider allocating
a greater proportion of resources to secondary data
analyses of existing clinical trials, which may help
to answer important questions without requiring
new data collection.
Furthermore, finding a good instrument may be difficult
[12]. Use of suboptimal instruments can raise concerns
about bias and undermine confidence in the study results
[13]. Propensity scores also have limitations as they cannot
adjust for unobserved characteristics that may differ be-
tween groups [13] and may introduce bias if IVs are unwit-
tingly included in the propensity score [14].
We believe that clinical trials and observational studies
play complementary roles and that both will be essential
to advance CER. Because most reports in this monograph
focus on observational approaches to CER, we examine
the use of clinical trials for CER with particular attention
to mental health care research. We outline some of the sit-
uations in which clinical trials may be feasible and even
preferable to observational studies and provide illustrative
examples, some of them based on our own work.2. Lack of established treatment or model of care for
a disorder
Although data from observational studies could in the-
ory suggest which treatments might be most promising
when there are no established treatments for a disorder, in
practice observational studies seldom offer sufficiently
fine-grained information to assess treatment fidelity, al-
though pharmacologic CER, which relies on prescription
claims data, offers a possible exception. The absence of de-
tailed but crucial information can lead to confounding the
potential efficacy of a treatment with the fidelity of its de-
livery. This may be particularly important in psychotherapystudies, in which the effective ‘‘dose’’ of treatment received
is directly linked to the quality of the treatment. Psycho-
therapy treatment, even when manualized, is much more
difficult to standardize than medication treatment, making
it difficult to monitor through claims data, electronic med-
ical records, or by noting the number and duration of the
therapy sessions. Although it would be possible to collect
this detailed information in observational studies, the cost
and complications associated with such data collection,
particularly in large studies, might make such observational
studies less attractive than corresponding clinical trials.
Thus, in deciding which design to choose, there may be
trade offs between the level of detail usually obtained in
a clinical trial and the sample size and length of follow-
up that are common in observational studies.
We faced this choice when seeking to study the treat-
ment of major depressive disorder (MDD) in women with
breast cancer. Although the treatment of mood disorders
in otherwise healthy individuals has been extensively stud-
ied, most existing research on MDD has focused on indi-
viduals with little or no comorbidity, particularly with
general medical conditions [15e17]. This gap in knowl-
edge is important because general medical conditions are
often associated with increased prevalence of MDD
[18,19], and comorbidity can adversely affect the outcome
of MDD [15,16]. A few published controlled trials of med-
ication or psychotherapy in depressed cancer patients with
promising but inconclusive results [20e22] prompted the
National Institutes of Halth and the Institute of Medicine
to call for well-designed controlled trials for the treatment
of depression in cancer patients [23,24].
Although it would have been possible to conduct an ob-
servational study of patients diagnosed with MDD by their
oncologists, we were concerned that many patients with
MDD would not be diagnosed and, even if they were diag-
nosed and were referred for psychotherapy, it would be dif-
ficult to assess the quality of the treatment received. This
would lead to results with low generalizability because of
sample selection issues and limited credibility because of
unknown treatment fidelity and thus unsuitable to guide
evidence-based treatment of MDD in this population. Based
on this reasoning, we decided to conduct a randomized clin-
ical trial, its main features are summarized in Table 1.
The challenges present in the study of depression in
breast cancer extend to the treatment of depression in indi-
viduals with other types of cancer or in the context of med-
ical illness. More generally, the issues of lack of standard
treatment go beyond testing the efficacy of specific treat-
ment modalities for specific populations and include lack
of standard models of care in particular settings. For exam-
ple, although collaborative models of care have shown
promise [25e27], they may require substantial modification
to be sustainable outside the context of highly organized,
well-financed integrated systems of care. Even less is
known about the treatment of anxiety disorders among per-
sons with general medical conditions. A recent study
Table 1. Design characteristics of a clinical trial for the treatment of depressed women with breast cancer (R01 CA133050)
Outline Characteristics
Objective To compare the efficacy of three types of psychotherapy in improving depressive symptoms and quality of life
among patients with BC and major depressive disorder (MDD).
Background  Up to 38% of cancer patients meet criteria for MDD, and another 20% of cancer patients have depressive
symptoms.
 Depression worsens over the course of cancer treatment, persists long after cancer therapy, and negatively
affects patients’ adherence to cancer treatment and survival.
 Clinical trials for MDD systematically exclude cancer patients and individuals with other medical illnesses,
rendering those studies nongeneralizable to these special populations.
Sample 150 Adult patients with BC stages IeIV who meet diagnostic criteria for MDD (English and Spanish speakers).
Sessions Twelve 50-minute sessions over 16 weeks and assessed 2 and 4 months after treatment.
Design Randomization in three types of psychotherapy.
Types of psychotherapies
Interpersonal psychotherapy  Flexibility and efficacy across different samples.
 Hypothesized mechanism of action: improving interpersonal relationships leads to improvement in depressive
symptoms and quality of life.
Problem-solving therapy  Brief form of cognitive behavioral therapy.
 Hypothesized mechanism of action: increased optimism, improved emotional regulation, successful resolu-
tion of stressful problems, and improved mood symptoms.
Brief supportive psychotherapy  Unstructured psychotherapy focused on the patient’s affect.
 Promotes strong therapeutic alliance through careful empathic listening and validating and encouraging
toleration of the patient’s emotions.
 Hypothesized mechanism of action: improve depressed mood by strengthening the patient’s mechanisms of
defense.
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chotherapy for a broad range of anxiety disorders in pri-
mary care was superior to treatment as usual, although
the effect sizes were modest [28]. Nevertheless, given the
high prevalence of mood and anxiety disorders among indi-
viduals with general medical conditions [28] and the impact
of such disorders on both quality of life and treatment out-
comes [29], continuing to develop models of care for this
group of patients should be a high priority in mental health
services research.3. Sequential treatment or stepped care
Despite the efficacy of psychiatric treatments, many pa-
tients require augmentation strategies or a change of treat-
ment altogether. As interest grows in achieving higher
efficiency, faster functional recovery, and improved cost-
effectiveness, we need to increase our knowledge of opti-
mal treatment sequences for psychiatric disorders, which
is limited at present. The use of observational designs for
the study of sequential treatments may be problematic as
it may be difficult to model the heterogeneity of patient
populations or the process of treatment selection. For exam-
ple, it would be necessary to identify a valid instrument for
each step of the treatment sequence, and any bias inherent
in the instrument(s) at any step of the treatment sequence
would be carried over to subsequent steps. Given the diffi-
culty in identifying truly valid instruments [13], it is easy to
see the barriers in studying sequential treatments without
experimental data. An additional complication is that it
may be difficult to find observational data in which treat-
ments were provided to patients for similar lengths of time
at each step of the sequences being compared. Problems inmodeling attrition would further complicate the interpreta-
tion of observational data it may be even more difficult to
model the dropout mechanism in studies of sequential treat-
ment than in studies with simpler designs. New methodo-
logical developments that address the current limitations
would be an important contribution to CER.
In the absence of the analytical tools needed to study se-
quential treatments with observational data, a few large
pragmatic trials in psychiatry have attempted to provide an-
swers to questions regarding sequential treatment of MDD
(e.g., STAR*D), bipolar disorder (e.g., STEP-BD), and
schizophrenia (e.g., CATIE). Although conducting such
large studies requires relatively large upfront costs, they
can also generate sizeable bodies of important information.
For example, CATIE challenged the common belief that
second-generation antipsychotics were generally superior
to first-generation antipsychotics in forestalling all-source
treatment discontinuation in schizophrenia [30]. Because
the cost of antipsychotics is so high [31], even a small
evidence-based decrease in the use of second-generation
antipsychotics could justify the cost of CATIE. Similarly,
the burden of disease of MDD and bipolar disorder is so
high [32,33] that even modest improvements in their treat-
ment would have a major impact at the population level.
Progress in SMART designs [34] may help to increase
the efficiency and affordability of future sequential trials.4. Treatments with high dropout rates
Clinical trials may also be useful in the study of treat-
ments with high dropout rates. Such as individuals with
pathological gambling (PG), substance use disorders or
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likely to occur at random, inferences drawn from these data
may not be valid without statistical adjustment; however,
such adjustments may not be feasible. For example, the use
of inverse probability weighting requires that the weights ap-
propriately model the true pattern of dropout [13], which is
difficult to do without knowing the reasons for dropout. Pa-
tients may drop out for several reasons, including early im-
provement, failure to improve, or other reasons [35].
Without detailed information, it may be difficult to differen-
tiate among these possibilities and to model them.
Clinical trials are also useful in clinical contexts with
high dropout rates because high dropout rates generally
lead to low or modest treatment effectiveness and may in-
dicate a need to modify the treatment or develop new alter-
native treatments. If dropout is because of patient
ambivalence about treatment [36,37], motivational inter-
viewing and related techniques might be useful as we hope
to demonstrate in an ongoing trial for the treatment of PG
(summarized in Table 2). Although cognitive-behavioral
therapy (CBT) is the most widely researched and promising
intervention for PG [38,39], dropout rates of 40e50% in
CBT clinical trials of PG limit its effectiveness. Because
pathological gamblers [38,40,41] experience ambivalence
toward quitting [36,42], we sought to compare CBT with
an augmented psychotherapy that combines CBT with mo-
tivational interviewing. Motivational interviewing is a cli-
ent-centered intervention that helps to build patient
motivation based on the discrepancy between the patient’s
values and the patient’s behaviors [36]. Our study is based
on the hypothesis that increasing patients’ motivation will
lead to increased retention in treatment. In other cases, such
as exposure-based approaches to PTSD or other anxiety
disorders, dropout may occur because of patients’ difficultyTable 2. Design features of clinical trial to improve retention in the treatme
Outline
Objective To improve retention and o
To examine mediators and
Background  PG is a persistent and re
increased preoccupation
spite adverse consequen
 PG is associated with sub
physical health, and elev
more than $5 bn.
Sample 200 patients meeting the D
Sessions 12 weekly sessions
Design Randomization in 2 types o
Types of Psychotherapies
Cognitive Behavioral Therapy (CBT)  The most widely research
 It corrects pathological g
emotional coping skills.
 Efficacious but with high
Cognitive Motivational Behavioral Therapy
(CMBT)
 It retains the strategies u
 It incorporates motivatio
 If retention in treatment
improved outcomes.
Abbreviation: DSM-IV, Diagnostic and Statistical Manual of Mental Disotolerating treatment procedures [43e45]. Preliminary data
suggest that alternative treatment approaches [e.g., interper-
sonal psychotherapy (IPT)] based on different mechanisms
of action may help to improve both retention and outcomes
for these patients [46]. Studies comparing the effectiveness
of exposure and prevention of response therapy vs. IPT are
ongoing (R01 MH079078: PI, Markowitz).5. Study of populations for whom observational data
may not exist
Clinical trials can also inform CER when observational
data may be scarce or even absent because of problems
with service access. In these cases, individuals who access
services and remain in treatment are unlikely to represent
persons in need of treatment [16,47]. The statistical model-
ing of barriers to treatment access and retention could be
quite challenging. For example, Hispanics have difficulties
with access to and retention in treatment because of com-
plex reasons that include cultural beliefs about disorders
and their treatment, lack of insurance or financial barriers,
logistical difficulties (e.g., lack of Spanish-speaking clini-
cians and inability to pay for childcare during treatment
visits), lack of trained professionals to deliver the treat-
ments and low quality of care received [33,35,48e55]. In
addition, after entry into treatment, Hispanics attend signif-
icantly fewer mental health sessions [54e64]. Several of
these barriers are also present in the treatment of individ-
uals who live in rural or remote areas, speak only a language
for which there is scarcity of therapists, or to the treatment
of co-occurring psychiatric disorders among patients in
substance abuse treatment.
As a potential solution that may improve access to treat-
ment, retention and response among depressed Hispanicsnt of pathological gambling (PG) (R01 MH082773)
Characteristics
utcomes of PG.
moderators of efficacy.
current maladaptive pattern of gambling behavior characterized by
with gambling activities, loss of control, and continued gambling de-
ces.
stantial personal and social costs, high comorbidity, poor mental and
ated suicide rates. The annual cost of PG to society is estimated at
SM-IV criteria for PG.
f psychotherapy.
ed and promising intervention for PG.
amblers’ distorted beliefs and teaches them cognitive, behavioral, and
drop-out rates.
sed in CBT
nal interviewing (MI) to improve retention
mediates abstinence from gambling, higher retention should lead to
rders, Fourth Edition.
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treatment approaches, we are comparing pharmacotherapy
(as a proxy for usual care) vs. a novel intervention in which
subjects are allowed to choose pharmacotherapy, IPT, or
their combination and are allowed (but not required) to re-
ceive 75% of the psychotherapy sessions by telephone. Fur-
thermore, in the novel intervention, patients are allowed to
switch treatment modality (e.g., from IPT alone to com-
bined treatment) at any point during the study period in
a negotiated approach with their psychiatrist as would hap-
pen in regular clinical care. We hypothesize that by permit-
ting patient choice among evidence-based treatments,
flexibility in the sequential use of treatments, and novel
treatment delivery systems, this intervention will substan-
tially increase retention of Hispanics in MDD treatment.
The design features of the trial are summarized in Table 3.
Other examples in which clinical trials may be prefera-
ble to observational studies include populations that rarely
seek treatment for their disorders [65] or the study of mo-
dalities such as telepsychiatry and behavioral telehealth
for which evidence of efficacy is limited and mode and fre-
quency of administration are yet to be optimized [66,67].
Observational data may be superior to clinical trials in pop-
ulations with extensive distrust of participating in research,
which would lead to nonrepresentative samples in clinical
trials, or when the prevalence of a disorder may be low,
but access to treatment is not restricted and can generate
representative samples.6. Examination of mediators and moderators of
treatment response
Clinical trials can also generally allow for a more refined
examination of potential mediators of efficacy and canTable 3. Design characteristics of a study to improve access and retention a
Outline
Objective To test the effectiveness of a novel
Hispanics.
Background  Hispanics receive poorer quality o
 After entry into treatment, Hispan
Hispanic whites.
Sample 170 Hispanic patients with a diagn
Main outcome measures Depressive symptoms 12 weeks afte
Design Randomized trial of antidepressants
psychotherapy, or combined med
Patients are allowed to switch treat
approach with their psychiatrist.
Patient treatment concerns targeted
 Offering choice of treatment
 Allowing telephonic sessions
 Extended clinic hours (until 8 pm
 Culturally congruent psychotherap
Patient’s concerns and expectations
Types of treatment
Medication Texas Medication Algorithm for Dep
Interpersonal psychotherapy (IPT)a 12-Session treatment course over 1
Combined medication plus IPT
a See description of IPT in Table 1.eventually identify the mechanism of action of the treat-
ment [68]. Knowing the mechanism of action of a treatment
can be extremely helpful in tailoring that treatment to dif-
ferent populations without losing its active ingredients.
For example, in our study of PG, we hypothesize that
level of motivation mediates retention in treatment, and
therefore, motivational interviewing by increasing motiva-
tion should improve retention. We further hypothesize that
changes in cognitions and behaviors associated with treat-
ment mediate gambling abstinence. Therefore, increased
retention in treatment should lead to a higher psychother-
apy ‘‘dose’’ and improved outcomes. In the study of the
treatment of MDD in breast cancer patients, we are exam-
ining not only symptom improvement but also potential
mediators that may help us to better understand the mech-
anism underlying of efficacy of other treatments.
Identification of moderators can help to delineate groups
for which specific treatments may be particularly useful and
identify subpopulations that require alternative approaches,
contributing to the provision of personalized medicine.
These analyses should help to develop sustainable forms
of treatment delivery that could be used in a variety of set-
tings. For example, treatment preference and level of moti-
vation are important predictors of outcome that are difficult
to evaluate outside the context of clinical trials [69].7. Secondary analyses of clinical trials
A final area in which clinical trials could significantly
contribute to CER is through secondary data analyses.
Partly because of the structure of the funding system, the
majority of the effort in clinical trials is currently devoted
to data collection, with very little time and financial support
allocated to analyses of existing data. This situation may bemong depressed Hispanics (R01 MH076051)
Characteristics
intervention to improve retention and response among depressed
f mental health care than non-Hispanic whites.
ics attend significantly fewer mental health sessions than non-
osis of major depressive disorder.
r treatment initiation.
vs. an experimental arm that allows for choice of medication,
ication and psychotherapy.
ment modality at any point during the study period in a negotiated
by
)
y
about MDD and its treatment are addressed in treatment.
ression
2 months
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formation. Funding agencies should consider allocating
more monies to analysis of existing data (e.g., through
grants or contracts that would fund additional analyses past
the time of the parent grant) and facilitate access to data
from public use data sets (e.g., STAR*D and STEP-BD)
from large clinical trials, or even data collected by the phar-
maceutical industry or regulatory agencies such as the
FDA, when those data could help to answer relevant ques-
tions. It would also be useful to devise funding mechanisms
to encourage individual investigators to make their data
available to other investigators after taking appropriate
measures to protect the privacy of the subjects. In the ab-
sence of funding for such efforts, investigators facing mul-
tiple demands are unlikely to have the time and resources to
share their data with other investigators or combine their
data with those from other laboratories to conduct addi-
tional analyses.8. Conclusions
We have briefly reviewed some situations in which clin-
ical trials may be preferable or offer complementary infor-
mation to observational studies for CER in mental health.
We believe that clinical trials have an important role in
CER on mental health, particularly with highly prevalent
disorders, when large effect sizes can be expected so that
they can be conducted with reasonable sample sizes, for
populations for which imputation of missing data would
lead to incorrect inferences, or for the study of sequential
treatment algorithms. At the same time, it is clear that with
limited resources, the answer to some questions will need
to be derived through the use of observational studies or
through secondary analyses of the existing data. In other
cases, it may be impossible to obtain sufficient information
to inform evidence-based medicine. As we continue to
strive to advance public health and improve patient care,
we face the challenge of prioritizing research resources in
a manner that optimally informs treatment decisions for
each individual patient.References
[1] Selby JV, Beal AC, Frank L. The Patient-Centered Outcomes Re-
search Institute (PCORI) national priorities for research and initial
research agenda. JAMA 2012;307:1583e4.
[2] Leon AC. Comparative effectiveness clinical trials in psychiatry:
superiority, noninferiority, and the role of active comparators. J Clin
Psychiatry 2011;72(10):1344e9.
[3] Kraemer HC. Another point of view: superiority, noninferiority, and
the role of active comparators. J Clin Psychiatry 2011;72(10):
1350e2.
[4] Zhu J, Sharma DB, Gray SW, Chen AB, Weeks JC, Schrag D. Car-
boplatin and paclitaxel with vs without bevacizumab in older pa-
tients with advanced non-small cell lung cancer. JAMA 2012;307:
1593e601.[5] Galvagno SM Jr, Haut ER, Zafar SN, Millin MG, Efron DT,
Koenig GJ Jr, et al. Association between helicopter vs ground emer-
gency medical services and survival for adults with major trauma.
JAMA 2012;307:1602e10.
[6] Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang YK, Sturmer T,
et al. Intensity-modulated radiation therapy, proton therapy, or con-
formal radiation therapy and morbidity and disease control in local-
ized prostate cancer. JAMA 2012;307:1611e20.
[7] Jackson RS, Chang DC, Freischlag JA. Comparison of long-term
survival after open vs endovascular repair of intact abdominal aor-
tic aneurysm among Medicare beneficiaries. JAMA 2012;307:
1621e8.
[8] Tan HJ, Norton EC, Ye Z, Hafez KS, Gore JL, Miller DC. Long-
term survival following partial vs radical nephrectomy among older
patients with early-stage kidney cancer. JAMA 2012;307:1629e35.
[9] Schneeweiss S, Patrick AR, Solomon DH, Mehta J, Dormuth C,
Miller M, et al. Variation in the risk of suicide attempts and com-
pleted suicides by antidepressant agent in adults: a propensity
score-adjusted analysis of 9 years’ data. Arch Gen Psychiatry
2010;67:497e506.
[10] Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H,
Brookhart MA. High-dimensional propensity score adjustment in
studies of treatment effects using health care claims data. Epidemi-
ology 2009;20:512e22.
[11] Bosco JLF, Silliman RA, Thwin SS, Geiger AM, Buist DSM,
Prout MN, et al. A most stubborn bias: no adjustment method fully
resolves confounding by indication in observational studies. J Clin
Epidemiol 2010;63:64e74.
[12] Greene W. Econometric analysis. 7th ed. New York, NY: Prentice
Hall; 2011.
[13] Concato J. Is it time for medicine-based evidence? JAMA 2012;307:
1641e3.
[14] Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate se-
lection in high-dimensional propensity score analysis of treatment
effects in small samples. Am J Epidemiol 2011;173:1410e3.
[15] Zimmerman M, Chelminski I, Posternak MA. Generalizability of
antidepressant efficacy trials: differences between depressed psychi-
atric outpatients who would or would not qualify for an efficacy
trial. Am J Psychiatry 2005;162(7):1370e2.
[16] Blanco C, Olfson M, Goodwin RD, Ogburn E, Liebowitz MR,
Nunes EV, et al. Generalizability of clinical trial results for major
depression to community samples: results from the National Epide-
miologic Survey on Alcohol and Related Conditions. J Clin Psychi-
atry 2008;69(8):1276e80.
[17] Khan A, Kolts RL, Thase ME, Krishnan KRR, Brown W. Research
design features and patient characteristics associated with the out-
come of antidepressant clinical trials. Am J Psychiatry 2004;
161(11):2045e9.
[18] Honda K, Goodwin RD. Cancer and mental disorders in a national
community sample: findings from the National Comorbidity Survey.
Psychother Psychosom 2004;73(4):235e42.
[19] Newport DJ, Nemeroff CB. Assessment and treatment of depression
in the cancer patient. J Psychosom Res 1998;45(3):215e37.
[20] van Heeringen K, Zivkov M. Pharmacological treatment of depres-
sion in cancer patients. A placebo-controlled study of mianserin. Br
J Psychiat 1996;169(4):440e3.
[21] Musselman DL, Lawson DH, Gumnick JF, Manatunga AK,
Penna S, Goodkin RS, et al. Paroxetine for the prevention of depres-
sion induced by high-dose interferon alfa. N Engl J Med 2001;344:
961e6.
[22] Ell K, Xie B, Quon B, Quinn DI, Dwight-Johnson M, Lee PJ. Ran-
domized controlled trial of collaborative care management of de-
pression among low-income patients with cancer. J Clin Oncol
2008;26:4488e96.
[23] Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM,
Krishnan K, et al. Mood disorders in the medically ill: scientific re-
view and recommendations. Biol Psychiatry 2005;58(3):175e89.
S35C. Blanco et al. / Journal of Clinical Epidemiology 66 (2013) S29eS36[24] Charney DS, Babich KS. Foundation for the NIMH strategic plan
for mood disorders research. Biol Psychiatry 2002;52(6):455e6.
[25] Woltmann E, Grogan-Kaylor A, Perron B, Georges H,
Kilbourne AM, Bauer MS. Comparative effectiveness of collab-
orative chronic care models for mental health conditions across
primary, specialty, and behavioral health care settings: system-
atic review and meta-analysis. Am J Psychiatry 2012;169(8):
790e804.
[26] Katon W, Russo J, Lin EHB, Schmittdiel J, Ciechanowski P,
Ludman E, et al. Cost-effectiveness of a multicondition collabora-
tive care intervention: a randomized controlled trial. Arch Gen Psy-
chiatry 2012;69:506e14.
[27] Pincus HA, Hough L, Houtsinger JK, Rollman BL, Frank RG.
Emerging models of depression care: multi-level (’6 P’) strategies.
Int J Methods Psychiatr Res 2003;12(1):54e63.
[28] Roy-Byrne P, Craske MG, Sullivan G, Rose RD, Edlund MJ,
Lang AJ, et al. Delivery of evidence-based treatment for multiple
anxiety disorders in primary care. JAMA 2010;303:1921e8.
[29] Comer JS, Blanco C, Hasin D, Liu SM, Grant BF, Turner JB,
et al. Health-related quality of life across the anxiety disorders:
results from the National Epidemiologic Survey on Alcohol and
Related Conditions (NESARC). J Clin Psychiatry 2011;72(1):
43e50.
[30] Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA,
Perkins DO, et al. Effectiveness of antipsychotic drugs in patients
with chronic schizophrenia. N Engl J Med 2005;353:1209e23.
[31] Alexander GC, Gallagher SA, Mascola A, Moloney RM,
Stafford RS. Increasing off-label use of antipsychotic medications
in the United States, 1995-2008. Pharmacoepidemiol Drug Saf
2011;20(2):177e84.
[32] Grant BF, Stinson FS, Hasin DS, Dawson DA, Chou SP, Ruan W,
et al. Prevalence, correlates, and comorbidity of bipolar I disorder
and axis I and II disorders: results from the National Epidemiologic
Survey on Alcohol and Related Conditions. J Clin Psychiatry 2005;
66:1205e15.
[33] Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of
major depressive disorder: results from the National Epidemiologic
Survey on Alcoholism and Related Conditions. Arch Gen Psychia-
try 2005;62:1097e106.
[34] Lei H, Nahum-Shani I, Lynch K, Oslin D, Murphy SA. A
‘‘SMART’’ design for building individualized treatment sequences.
Annu Rev Clin Psychol 2012;8:21e48.
[35] Sanchez-Lacay JA, Lewis-Fernandez R, Goetz D, Blanco C,
Salman E, Davies S, et al. Open trial of nefazodone among His-
panics with major depression: efficacy, tolerability, and adherence
issues. Depress Anxiety 2001;13(3):118e24.
[36] Miller WR, Rollnick S. Motivational interviewing: preparing people
for change. New York, NY: Guilford Press; 2002.
[37] Petry NM, Stinson FS, Grant BF. Comorbidity of DSM-IV patho-
logical gambling and other psychiatric disorders: results from the
National Epidemiologic Survey on Alcohol and Related Conditions.
J Clin Psychiatry 2005;66(5):564e74.
[38] Petry NM, Ammerman Y, Bohl J, Doersch A, Gay H, Kadden R,
et al. Cognitive-behavioral therapy for pathological gamblers.
J Consult Clin Psych 2006;74(3):555e67.
[39] Sylvain C, Ladouceur R, Boisvert JM. Cognitive and behavioral
treatment of pathological gambling: a controlled study. J Consult
Clin Psych 1997;65(5):727e32.
[40] Blanco C, Moreyra P, Nunes E, Saiz-Ruiz J, Iba~nez A. Pathological
gambling: addiction or compulsion? Semin Clin Neuropsychiatry
2001;6(3):167e76.
[41] Blanco C, Myers J, Kendler KS. Gambling, disordered gambling
and their association with major depression and substance use:
a web-based cohort and twin-sibling study. Psychol Med 2012;42:
497e508.
[42] Petry NM. Stages of change in treatment-seeking pathological gam-
blers. J Consult Clin Psych 2005;73(2):312e22.[43] Pitman RK, Altman B, Greenwald E, Longpre RE, Macklin ML,
Poire RE, et al. Psychiatric complications during flooding therapy
for posttraumatic stress disorder. J Clin Psychiatry 1991;52:
17e20.
[44] Scott MJ, Stradling SG. Client compliance with exposure treatments
for posttraumatic stress disorder. J Trauma Stress 1997;10(3):
523e6.
[45] Foa EB, Rothbaum BO, Furr JM. Augmenting exposure therapy
with other CBT procedures. Psychiat Ann 2003;33:47e53.
[46] Bleiberg KL, Markowitz JC. A pilot study of interpersonal psycho-
therapy for posttraumatic stress disorder. Am J Psychiatry 2005;
162(1):181e3.
[47] Blanco C, Olfson M, Okuda M, Nunes EV, Liu SM, Hasin DS. Gen-
eralizability of clinical trials for alcohol dependence to community
samples. Drug Alcohol Depend 2008;98(1):123e8.
[48] Blanco C, Patel SR, Liu L, Jiang H, Lewis-Fernandez R,
Schmidt AB, et al. National trends in ethnic disparities in mental
health care. Med Care 2007;45:1012e9.
[49] Lewis-FernandezR, Balan IC, Patel SR, Sanchez-LacayA,AlfonsoC,
GorritzM, et al. Impact ofmotivational pharmacotherapy on treatment
retention among depressed Latinos. Psychiatr in Press.
[50] Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA,
Walters EE, et al. Prevalence and treatment of mental disorders,
1990 to 2003. N Engl J Med 2005;352:2515e23.
[51] Sclar DA, Robison LM, Skaer TL, Galin RS. Ethnicity and the pre-
scribing of antidepressant pharmacotherapy: 1992-1995. Harv Rev
Psychiat 1999;7(1):29e36.
[52] Young AS, Klap R, Sherbourne CD, Wells KB. The quality of care
for depressive and anxiety disorders in the United States. Arch Gen
Psychiatry 2001;58:55e61.
[53] Lagomasino IT, Dwight-Johnson M, Miranda J, Zhang L, Liao D,
Duan N, et al. Disparities in depression treatment for Latinos and
site of care. Psychiatr Serv 2005;56(12):1517e23.
[54] Miranda J, Azocar F, Organista KC, Dwyer E, Areane P. Treatment
of depression among impoverished primary care patients from eth-
nic minority groups. Psychiatr Serv 2003;54(2):219e25.
[55] Miranda J, Duan N, Sherbourne C, Schoenbaum M, Lagomasino I,
Jackson-Triche M, et al. Improving care for minorities: can quality
improvement interventions improve care and outcomes for de-
pressed minorities? Results of a randomized, controlled trial. Health
Serv Res 2003;38:613e30.
[56] Hough RL, Landsverk JA, Karno M, Burnam MA, Timbers DM,
Escobar JI, et al. Utilization of health and mental health services
by Los Angeles Mexican Americans and non-Hispanic whites. Arch
Gen Psychiatry 1987;44:702e9.
[57] Wells KB, Golding JM, Hough RL, Burnam MA, Karno M. Factors
affecting the probability of use of general and medical health and
social/community services for Mexican Americans and non-
Hispanic whites. Med Care 1988;24:441e52.
[58] Wells KB, Golding JM, Hough RL, Burnam MA, Karno M. Accul-
turation and the probability of use of health services by Mexican
Americans. Health Serv Res 1989;24:237e57.
[59] Vega WA, Kolody B, Aguilar-Gaxiola S, Catalano R. Gaps in ser-
vice utilization by Mexican Americans with mental health prob-
lems. Am J Psychiatry 1999;156(6):928e34.
[60] Marcos LR, Cancro R. Pharmacotherapy of Hispanic depressed pa-
tients: clinical observations. Am J Psychother 1982;36:505e12.
[61] Vega WA, Warheit G, Buhl-Auth J, Meinhardt K. The prevalence of
depressive symptoms among Mexican Americans and Anglos. Am J
Epidemiol 1984;120:592e607.
[62] Harman JS, Edlund MJ, Fortney JC. Disparities in the adequacy of
depression treatment in the United States. Psychiat Serv 2004;
55(12):1379e85.
[63] Miranda J, Cooper LA. Disparities in care for depression among pri-
mary care patients. J Gen Intern Med 2004;19:120e6.
[64] Dwight-Johnson M, Unutzer J, Sherbourne C, Tang L, Wells KB.
Can quality improvement programs for depression in primary care
S36 C. Blanco et al. / Journal of Clinical Epidemiology 66 (2013) S29eS36address patient preferences for treatment? Med Care 2001;39:
934e44.
[65] Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC.
Twelve-month use of mental health services in the United States: re-
sults from the National Comorbidity Survey Replication. Arch Gen
Psychiatry 2005;62:629e40.
[66] McGinty KL, Saeed SA, Simmons SC, Yildirim Y. Telepsychiatry
and e-mental health services: potential for improving access to men-
tal health care. Psychiatr Q 2006;77(4):335e42.[67] Nelson EL, Bui TN, Velasquez SE. Telepsychology: research and
practice overview. Child Adolesc Psychiatr Clin N Am 2011;
20(1):67e79.
[68] Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and
moderators of treatment effects in randomized clinical trials. Arch
Gen Psychiatry 2002;59:877e83.
[69] Simon GE, Perlis RH. Personalized medicine for depression: can we
match patients with treatments? Am J Psychiatry 2010;167(12):
1445e55.
